Announced Date: 2023-01-23 (January 23, 2023)
Asset Name: Fruquintinib
Licensor: HutchMed (China)
Licensee (Buyer): Takeda (Japan)
.
Asset Modality: Small Molecule, Oral
Asset Target: VEGFR1/2/3 Tyrosine Kinase Inhibitor
Potential Indication: Refractory Metastatic Colorectal Cancer
Current Stage: Fruquintinib, approved in China in 2018; With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023
.
Scope of Authority:
Takeda will receive an exclusive worldwide license to develop and commercialize fruquintinib in all indications and territories outside of mainland China, Hong Kong and Macau.
.
Deal Detail:
Upfront payment of $400 million,
Milestone payments up to $730 million.
Royalties on net sales.
.
Link:
